Effect of ivermectin on the liver of gilthead seabream Sparus aurata: a proteomic approach by Varó, Inmaculada et al.
 1 
 1 
 2 
 3 
EFFECT OF IVERMECTIN ON THE LIVER OF GILTHEAD SEABREAM Sparus 4 
aurata: A PROTEOMIC APPROACH 5 
 6 
VARÓ, I1;2 *; RIGOS, G3; NAVARRO, J.C2; DEL RAMO, J1; CALDUCH-GINER, J2 ; HERNÁNDEZ, A1;  ; 7 
J. PERTUSA1;TORREBLANCA, A1 8 
 9 
 10 
1 Department of Functional Biology, Faculty of Biological Sciences, University of Valencia. Dr. Moliner, 11 
50, 46100 Burjassot, Valencia, Spain. 12 
 13 
2 Instituto de Acuicultura de Torre de la Sal (CSIC), 12595 Ribera de Cabanes, Castellón, Spain  14 
 15 
3 Institute of Aquaculture, Hellenic Centre for Marine Research (HCMR). Aghios Kosmas 16777, 16 
Ellinikon, Attiki, Greece. 17 
 18 
*Corresponding author. Present address: Instituto de Acuicultura de Torre de la Sal (CSIC), 19 
12595 Ribera de Cabanes, Castellón, Spain.  20 
Tel: +34 964 319500 ext 15 21 
Fax: +34 964 319509 22 
email: inma@iats.csic.es 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
  32 
*Manuscript
Click here to view linked References
 2 
ABSTRACT   33 
Gilthead sea bream Sparus aurata is the most commercialized Mediterranean aquacultured 34 
fish species. Ivermectin has recently (experimentally) started to be used to control 35 
ectoparasitic infestations in Mediterranean cultured marine fish. The potential hepatotoxicity 36 
of ivermectin was investigated in gilthead sea bream juveniles (35 g) following oral 37 
administration at the recommended dose of 0.2 mg kg-1 fish for 10 days. Difference Gel 38 
Electrophoresis Technology (DIGE) was used to study the effect of this treatment in gilthead 39 
sea bream liver protein profile under routine culture conditions. The 2D-DIGE protein maps 40 
obtained were analyzed using the DeCyder 6.5 software. The results obtained showed 41 
significant changes in the expression of 36 proteins respect to the control group. Among 42 
these proteins, six increased in abundance, and 30 decreased. Spot showing differential 43 
expression respect to the control were analysed by mass spectrometry and database search, 44 
which resulted in three positive identifications corresponding to hepatic proteins involved in 45 
lipid metabolism (apoA-I), oxidative stress responses and energy generation (beta-globin, 46 
ATP synthase subunit beta). These proteins have not been previously associated to 47 
invermectin effect. 48 
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 Introduction  70 
 Gilthead sea bream, (Sparus aurata) is the most important Mediterranean 71 
aquacultured fish species. As with other intensive animal farming practices, aquaculture 72 
activities involve the cultivation of large numbers of fish confined in a reduced space and 73 
therefore, disease outbreaks are common regardless of the improvement of vaccine 74 
development and the quality of the hygiene practised. Pathogens such as bacteria, parasites, 75 
viruses and fungi may cause infection in cultured fishes. Disease outbreaks in aquaculture 76 
are normally confronted with mass therapy, usually orally administered via incorporation of 77 
drugs into the feed. It is generally accepted that nowadays exoparasitic outbreaks remain the 78 
most significant source of mortalities in Mediterranean fish cage farming (Rigos and 79 
Katharios, 2009). 80 
Ivermectin, is a wide spectrum antiparasitic drug, belonging to the family of 81 
avermectins. Avermectins are macrocyclic lactones isolated from the fermentation products 82 
of the actinomycetes Streptomyces avermitilis (Campell et al., 1983). The general mode of 83 
action of these compounds is to interrupt the transmission of signals in the nervous system of 84 
invertebrates. The high-affinity binding of avermectins to glutamate-gated chloride ion 85 
channels in invertebrate excitable cells leads to paralysis and death (Arena et al., 1995). 86 
These neurotoxins are highly effective when used against arthropod and nematode infections 87 
in a number of terrestrial farm animals (Campell, 1989), and also in the prevention of some 88 
parasitic infections in humans, like river blindness (onchocerciasis) (Laffont et al., 2002).  89 
In Atlantic salmon (Salmo salar) sea lice infestations produce general stress and 90 
osmorregulatory problems due to disruption of the skin by the feeding behavior of the 91 
parasites, as well, as changes in the feeding behavior of fish (Dawson et al., 1999). Although 92 
according to Sanderson et al. (2007) ivermectin has not officially been used for ectoparasite 93 
treatment in aquaculture, it has been used “de facto” for the control of sea lice in salmon 94 
farms in Chile, Ireland, Canada and UK (Roth, 2000). Besides, this drug has also started to 95 
be used in Mediterranean aquaculture to control ectoparasitic copepod (Lernathropus 96 
kroyeri) and isopod (Ceratothoa oestroides) infestations (Athanassopoulou et al., 2001).  97 
Several authors have reported the efficacy and toxicity of ivermectin against 98 
ectoparasitic infestations of several farmed fish (Palmer et al., 1987; Spencer, 1992; Davies 99 
and Rodger, 2000; Athanassopoulou et al., 2001, 2002; Katharios et al., 2002a, 2004; 100 
Mladineo et al., 2006). The most commonly used oral doses in farmed fish range between 101 
0.05 and 0.2 mg kg-1 fish, with different schemes of administration (i.e. single dose, once or 102 
twice a week), without apparent side effects to the fish (Palmer, et al., 1987; Johnson et al., 103 
1993; Davies and Rodger, 2000; Athanassopoulou et al., 2001).  104 
Regarding pharmacokinetics, ivermectin is accumulated in fatty tissues including liver, 105 
and exhibits an enterohepatic circulation in vertebrates (Davies and Roger, 2000). Katharios 106 
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et al. (2002a) obtained a rapid uptake, high bioavailabilty and fast elimination in gilthead sea 107 
bream after intraperitoneal injection of ivermectin. However, when the drug was orally 108 
administered, a slow absorption and elimination profile was evident, with bile being the major 109 
route of excretion mainly as parent drug (Hoy et al., 1990). Furthermore, the high brain 110 
concentrations of ivermectin found in Atlantic salmon, Salmon salar, and gilthead sea bream 111 
after oral and intraperitoneal administration, respectively (Hoy et al., 1990; Katharios et al., 112 
2002a, 2004) point towards a less selective barrier in fish as compared to mammals. 113 
Katharios et al. (2002b) investigated the toxic side effects of ivermectin administrated 114 
intraperitoneally to gilthead sea bream at single doses of 0.1, 0.2, 0.4 and 0.8 mg Kg-1 fish. 115 
Their study concluded that the most important side effect of ivermectin was a significant 116 
reduction of the hematocrit value in fish treated with the highest dose (0.8 mg kg-1 fish). Also, 117 
signs of neurotoxicity like lethargy, loss of appetite and dark color were observed at this 118 
dose. However, neither mortality nor histopathological alterations in the different tissues 119 
examined including liver were observed.  120 
Up to date, all previous works on the toxicity effect of ivermectin in marine fish, 121 
including gilthead sea bream, have been carried out using conventional approaches, and no 122 
studies have been published about the capacity of the drug to produce liver injury at the 123 
molecular level after a standard treatment. Recently, the introduction of new and improved 124 
proteomic technology, has allowed investigating changes in biological events at molecular 125 
level. Proteomics-based approaches have a great potential since they massively assess 126 
protein alterations without any previous knowledge of toxicity mechanisms (López-Barea and 127 
Gómez-Ariza, 2006), and may be useful to find new biomarkers of hepatotoxicity in animals, 128 
including marine fish. 129 
The aim of this study was to evaluate the possible hepatotoxicity effects of ivermectin 130 
in gilthead sea bream juveniles after oral administration at the recommended dose of 0.2 mg 131 
kg-1 fish. The liver was examined as the principal target of toxicity due to the role of this 132 
organ in energetic and xenobiotic metabolism. To evaluate the effect of the treatment, a 133 
proteomic approach was carried out using 2-D differential gel electrophoresis (2D-DIGE) and 134 
proteins of interest were identified by mass spectrometry analysis and database search. 135 
 136 
 Materials and Methods 137 
Animals and treatment 138 
 Gilthead sea bream weighting 35  9 g were purchased from a local commercial 139 
aquaculture farm (Acuícola Marina SL, Burriana, Castellón, Spain), and kept in the facilities 140 
of the aquarium plant of the University of Valencia. Fish were distributed in several 2000 L 141 
fibreglass tanks (120 fish per tank) filled with seawater (salinity: 32‰) supplied with 142 
 5 
continuous aeration under room temperature (19 ± 0.5 ºC) in a closed circuit, and acclimated 143 
for 1 week before starting the experiment.  144 
The test fish were fed pelleted dry food medicated with ivermectin at a concentration 145 
of 0.2 mg kg-1 fish, for 10 days (1% body weight daily feeding ratio with fish delivered feed 146 
once a day). The control fish were administered unmedicated pelleted feed at the same 147 
feeding schedule. The experimental feeds were made at the Fish Nutrition and Pathology 148 
Laboratory, Institute of Aquaculture, of the Hellenic Center for Marine Research in Athens 149 
(Greece). Commercial feed (Biomar) with the following composition: fish meal (35%), soya 150 
bean meal (20%), wheat meal (15%), rapeseed meal (2.7%), wheat gluten (5%), corn gluten 151 
(10%), fish oil (13%), premix (0,3%). Ingredients were grounded, mixed with the antiparasitic 152 
drug, and prepared as dry pellets suitable for the size of the fish. The same procedure was 153 
followed for the preparation of the unmedicated diet. 154 
 After treatment, 8 fish from each experimental group were anaesthetized with clove 155 
oil (20 mg L-1) and sacrificed before livers being quickly dissected. The samples were 156 
immediately frozen in liquid nitrogen and stored at -80 ºC until analyzed. 157 
 158 
2-D difference gel electrophoresis (2D-DIGE)  159 
 Liver homogenization and protein labelling  160 
Individual livers were homogenized with the aid of a grinding kit system (General 161 
Electric Healthcare) in 9 volumes of DIGE buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 162 
mM Tris) in which antiproteolytic agent (Complete Mini Roche) was added. The solubilized 163 
proteins were separated from non-solubilized cellular components by centrifugation (20,000 164 
g x 20 min). Proteins present in the supernatants were precipitated using the 2D Clean-up kit 165 
(GE Healthcare, Uppsala, Sweden) according to the manufacturer’s instructions and 166 
resolublized in DIGE buffer. The pH of protein extract was adjusted to 8.5 by adding 50 mM 167 
NaOH, and protein concentration was determined using the Bradford Biorad Protein Assay 168 
(RcDc kit) with -globulin as standard.  169 
Liver proteins extracted from control (n=8) and treated (n=8) fishes were randomly 170 
labelled with Cy3 or Cy5. For DIGE minimal labelling, 50 µg of protein sample was mixed 171 
with 400 pmol CyDye (GE healthcare) by vortexing and incubated on ice in the dark for 30 172 
min. The labelling reaction was stopped by the addition of 1 µL 10 mM lysine followed by 173 
incubation on ice for a further 10 min. The internal standard sample was prepared by pooling 174 
25 µg of protein from each liver sample studied and by labelling by Cy2 as above described. 175 
Combinations of a Cy3 and a Cy5 labelled sample were then mixed with Cy2-labeled internal 176 
standard, and DTT (65 mM final concentration) and ampholytes (1% final concentration, pH  177 
= 3-10) were added to the mixture before running the first dimension.  178 
 179 
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Gel electrophoresis (2D-DIGE gel) and image capture 180 
The 16 liver protein samples were analysed on a total of 8 analytical 2-D gels. IPG 181 
strips (24 cm, pH = 3-11NL) were rehydrated in 8 M urea, 4% CHAPS, DeStreak (12 µL mL-182 
1), and ampholytes (1% final concentration, pH = 3-10) overnight at room temperature. Cy-183 
labelled samples were applied onto IPG rehydrated strips via anodic cup loading, and IEF 184 
was performed on a Ettan IPGphor II horizontal electrophoresis system (Amersham 185 
Biosciences) at 20 °C using the following program:  step 1:300 V 4 h, gradient to 1000 V 6h, 186 
gradient to 8000 V 3 h; step 2: 8000 V until reached 32000 V h.  187 
After IEF, the strips were reduced in equilibration buffer (Tris 50 mM, urea 6 M and 188 
glycerol 30% (v/v), 2% SDS (w/v)) containing 2% DTT, for 15 min at room temperature; 189 
followed by alkylation in equilibration buffer containing 2.5% iodoacetamide, for 15 min at 190 
room temperature. 191 
Then, the strips were transferred to the second dimension 12.5% acrylamide SDS-192 
PAGE gels (25 cm x 21 cm x 1 mm) made between low fluorescence glass plates, and 193 
overlaid with 0.5% low melting agarose. The gels were run in Ettan Dalt Six Unit (GE 194 
Healthcare) electrophoresis system at 2 W per gel for 1 h and 15 W per gel for 6 h.  195 
 After electrophoresis, the 2-D gels were scanned directly in a TyphoonTM 9400 196 
Variable Mode Imager to visualize the labelled proteins. Excitation and emission wavelengths 197 
were chosen specifically for each of the dyes according to manufacturer’s recommendations. 198 
(GE Healthcare).  199 
 200 
Data analysis 201 
Intra-gel and Inter-gel matching and statistical analysis were performed using 202 
DeCyderTM V. 6.5 and DeCyderTM EDA software V.1.0. 203 
Gel images were processed by the DeCyder-DIA (Differential In-gel Analyses) 204 
software module to co-detect and differentially quantify the protein spots in the images, 205 
taking the internal standard sample as a reference to normalize the data. DIA software uses 206 
a normal distribution model to determine the differentially expressed spots. The threshold 207 
was set to 2 standard deviations based on an assumption that 95% of the protein spots were 208 
not expected to be differentially expressed. Each protein in the individual sample is 209 
represented in the pooled internal standard, thus a comparison between the test samples 210 
and the identical protein in the internal standard can be used to generate a ratio of relative 211 
expression. Then, the DeCyder-BVA (Biological Variation Analysis) was applied. BVA does a 212 
gel-to-gel matching of the internal standard spots maps from each gel. The differences in 213 
average ratios of protein expression were analysed by the Student´s t- test (p ≤ 0.02). 214 
EDA module from DeCyderTM software was used for multivariate statistical analysis of 215 
data.  Principal Components Analysis (PCA) was carried out following the nonlinear iterative 216 
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partial least squared method, including only proteins present in at least 80% of the spot maps 217 
and applying a t-test filter (p ≤ 0.02). A hierarchical cluster analyses was performed using the 218 
same protein selection criteria. 219 
 220 
Protein identification by mass spectrometry (MALDI, MS/MS) analysis  221 
Proteins of interest were manually excised from analytical gels and digested with 222 
sequencing grade trypsin (Promega) as described elsewhere (Shevchenko et al.1996), and 223 
subject to PMF (MALDI) and/or LC/MS/MS analyses. 224 
The digestion mixture was dried in a vacuum centrifuge, resuspended in 7 µL of 0.1% 225 
TFA (trifluoroacetic acid, Sigma), and 1 μL was spotted onto the MALDI target plate. After 226 
the droplets were air-dried at room temperature, 0.5 μL of matrix (5 mg mL-1 CHCA-227 
cyano-4-hydroxycinnamic acid, Sigma) in 0.1% TFA-ACN/H2O (1:1, v/v) was added and 228 
allowed to air-dry at room temperature. The resulting 576 fractions were analyzed in a 4700 229 
Proteomics Analyzer (Applied Biosystems, Foster City, USA) in positive reflection mode 230 
(2000 shots every position). Five of the most intense precursors (according to the threshold 231 
criteria: minimum signal-to-noise: 10, minimum cluster area: 500, maximum precursor gap: 232 
200 ppm, maximum fraction gap: 4) were selected for every position for the MS/MS analysis. 233 
And, MS/MS data corresponding to the control was acquired using the default 1 kV MS/MS 234 
method. 235 
The MS and MS/MS information was sent to MASCOT via the GPS software (Applied 236 
Biosystems). Database search on Swiss-Prot and NCBI databases was performed using 237 
MASCOT search engine (Matrix-Science). Searches were done with tryptic specificity 238 
allowing one missed cleavage and a tolerance on the mass measurement of 100 ppm in MS 239 
mode and 0.8 Da for MS/MS ions. Carbamidomethylation of Cys was used as a fixed 240 
modification and oxidation of Met and deamidation of Asn and Gln as variable modifications. 241 
The samples without a positive identification were analyzed by LC/MS/MS. Peptide 242 
separation by LC-MS/MS was performed using an Ultimate nano-LC system (LC Packings) 243 
and a QSTAR XL Q-TOF hybrid mass spectrometer (MDS Sciex-Applied Biosystems). 244 
Samples (5 µL) were delivered to the system using a FAMOS autosampler (LC Packings) at 245 
40 µL min-1, and the peptides were trapped onto a PepMap C18 pre-column (5 mm   300 m 246 
i.d.; LC Packings). Peptides were then eluted onto the PepMap C18 analytical column (15 247 
cm   75 m i.d.; LC Packings) at 200 nL min-1 and separated using a 55 min gradient of 15–248 
50% CAN. The QSTAR XL was operated in information-dependent acquisition mode, in 249 
which a 1-s TOF MS scan from 400–2000 m/z, was performed, followed by 3-s product ion 250 
scans from 65–2000 m/z on the three most intense doubly or triply charged ions. 251 
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The MS/MS information was sent to MASCOT via the MASCOT DAEMON software 252 
(MATRIX SCIENCE). The search parameters were defined as for MS-MS/MS analysis. 253 
 254 
Quantitative RT-PCR of selected proteins 255 
Total RNA was extracted from the same liver used for the proteomic analysis with the 256 
RNAspin MiniRNA isolation kit (GE HealthCare), according to the manufacturer´s 257 
instructions, and stored at -80 ºC. The purity and quantity of extracted RNA were measured 258 
with the Experion System (Bio-Rad). Two hundred ng of total RNA was reverse transcribed 259 
into cDNA using the High-Capacity cDNA reverse transcription kit (Applied Biosystems), with 260 
a final reaction volume of 20 µL. The RT conditions were: 10 min at 25 ºC, 120 min at 37 ºC 261 
and 5 sec at 85 ºC. The cDNA samples were stored at -20 ºC until use. 262 
 Transcript measurements were made by real-time PCR using an iCycler IQ Real-time 263 
Detection System (Bio-Rad, Hercules, CA, USA) as previously described (Calduch-Giner et 264 
al., 2003). RT reactions were conveniently diluted and 7.5 μL were used for PCR reactions in 265 
a 25 μL volume. Each PCR-well contained a SYBR Green Master Mix (Bio-Rad) with specific 266 
primers at a final concentration of 0.9 μM (see Table 1). Alpha-tubulin was used as 267 
housekeeping gene and the efficiency of PCR reactions for target and reference genes 268 
varied between 88% and 95%, respectively. The dynamic range of standard curves spanned 269 
five orders of magnitude, and the amount of product in a particular sample was determined 270 
by interpolation of the cycle threshold (Ct) value. The specificity of reaction was verified by 271 
analysis of melting curves. Fluorescence data acquired during the extension phase were 272 
normalized to α-tubulin by the delta-delta method (Livak and Schmittgen, 2001), using data 273 
in control fish as reference values. No changes in α-tubulin expression were found in 274 
response to treatment. 275 
The difference in gene expression levels between control and treated fish was 276 
calculated by two-tailed independent Student t-test using SPSS statistics software v 17.0. A 277 
p value  0.05 was considered statistically significant. 278 
 279 
Histology 280 
For histological analyses subsamples from the same liver used for the proteomic study were 281 
immediately fixed in buffered formalin at 4°C for 24 h. Samples were transferred to 70% 282 
alcohol and kept there until processing. Finally, samples were dehydrated in alcohol, wax-283 
embedded, cut into 6 µm sections and stained with the hematoxylin and eosin technique. 284 
 285 
Results  286 
A representative 2D-DIGE-gel image of total liver proteins extracts from treated 287 
versus control fish is shown in Figure 1.  Proteins over the range of pH applied in this 288 
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experiment (pH = 3-11NL) and with a molecular weight from approximately 10 to 250 kDa 289 
were resolved, and 3993 spots in the master gel were detected using the DeCyder BVA 290 
software. Each protein spot was assigned an average ratio (i.e. change in expression level 291 
due to ivermectin treatment) and p-value (Student´s t-test) to indicate the level of 292 
significance. A total of 36 protein spots showed significant changes in the expression 293 
compared to the control group (standardized average volume ratio ≥ 1.3, t-student ≤ 0.02). 294 
This represented about 1% of the total protein spots analysed. Among these protein spots, 6 295 
were up regulated and 30 down regulated by ivermectin. The positions of those differentially 296 
expressed protein spots in the 2D-DIGE are shown in Figure 1. The PCA and hierarchical 297 
cluster analyses of data are shown in Figure 2. The PCA results obtained indicated that two 298 
components are enough to cluster the different experimental groups (control vs treated), with 299 
a clear separation in the first component (PC1) between them (Fig 2A). The pattern analyses 300 
showed a clustering in a hierarchical way, where protein maps corresponding to control 301 
group formed a cluster separated from those corresponding to the ivermectin treated group 302 
(Fig 2B) 303 
The results of protein identification by PMF and/or LC-MS/MS and data base research 304 
are listed in Table 2. The 2D-DIGE analyses (spot nº, protein name, MW/pI, gi accession 305 
number, p-value, and the average ratio/fold change) are also indicated in Table 2. Ten 306 
differentially expressed proteins were identified. It was found that five of theses proteins are 307 
related to the oxygen transport: beta globin (spots 3736, 3776, 3784, 3838 and 3841), two 308 
proteins are involved in the cholesterol metabolism: apo A-I (spot 3993 and 3992), and one 309 
protein is related in ATP synthesis: ATP synthase beta chain  (spot 3913). All of them were 310 
down regulated. Also, ivermectin induced remarkable changes in two proteins that have 311 
unknown function and were down regulated (spots 3074 and 3760). 312 
 Among the proteins identified, the beta globin and apo A-I were selected for gene 313 
expression analyses. Transcript abundance of beta globin and apo A-I were determined by 314 
quantitative PCR. Figure 3 shows transcript hepatic expression levels of beta globin and apo 315 
A-I. The expressions of both genes apparently decreased as a result of the ivermectin 316 
treatment (relative mRNA expression of beta globin: 1  0.69 vs 0.35  0.23, mean  std and 317 
relative mRNA expression of apo A-I: 1.04  0.32 vs 0.62  0.29), but there were not 318 
significant differences between control and treated fish (p  0.05). 319 
Structural or morphological differences were not observed between control and 320 
ivermectin treated livers, and no pathological alterations were found in the livers from fish 321 
treated with ivermectin (Fig 4). 322 
 323 
 324 
Discussion 325 
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As far as we know, this study represents the first proteomic approach to determine 326 
the potential hepatotoxicity of ivermectin in gilthead sea bream. Differential gel 327 
electrophoresis (2D-DIGE) allowed us to detect differences in the expression level of 36 328 
proteins, revealing the existence of effects of ivermectin treatment at recommended dose in 329 
gilthead sea bream. 330 
The concept of altered protein expression signatures (PES), i.e. a set of proteins 331 
observed in bidimensional electrophoresis (2-DE) as state markers signalling for early 332 
pathological stages or stress exposure, was first described by Shepard and Bradley (2000) 333 
and Shepard et al. (2000), and successfully used by Vioque-Fernández et al. (2009) for 334 
assessing toxicity caused by environmental pollutants in the red crayfish (Procambarus 335 
clarkii). According to the cluster analysis, the changes in relative abundance of a set of 36 336 
proteins that we have found is sufficient to discriminate spot maps corresponding to 337 
ivermectin treated fish from those corresponding to control fish. These changes seem to be 338 
preliminary to hepatotoxicity, or transient, since the histological analysis did not show hepatic 339 
damage. Therefore changes in this set of proteins can be considered as a very early PES of 340 
ivermectin standard treatments in this species. 341 
Eleven spots were characterised by PMF and /or LC-MS/MS and database research, 342 
From those, eight were positively identified and related to three main proteins associated to 343 
reverse transport of cholesterol and lipid metabolism (apoA-I) (2), oxygen transport (beta-344 
globin) (5), and ATP synthesis and transport (ATP synthase subunit beta) (1). These proteins 345 
have been previously identified and analysed in other organisms, including fish. 346 
ApoA-I is the major protein component of high-density lipoprotein (HDL), and in 347 
general, is synthesised predominantly in the liver and/or intestine in mammals, birds and fish. 348 
Although its typical role is the reverse transport of cholesterol from tissues to the liver, recent 349 
studies on fish apoA-I show that this protein is involved in many other functions. It is also 350 
known that, apo A-I has antimicrobial activity (Johnston et al., 2008) and is implicated in 351 
innate immunity in fish (Villarroel et al., 2007). However, the apoA-I responsible for this 352 
function is more abundantly expressed in the epidermis, gills and intestinal mucosa, than in 353 
the liver and plasma. Additionally, apoA-I has been involved in osmotic regulation in fish 354 
(Chen et al., 2009) 355 
 In the present work, apoA-I decreased significantly in liver as a consequence of 356 
ivermectin treatment. However, in the measured transcript significant differences were not 357 
found. Direct assumption of co-expression of mRNA leading to co-expression of protein has 358 
been recently questioned (Wang, 2008). 359 
Reduced expression of apoA-I has been observed in previous studies carried out in 360 
fish.  Kleveland et al. (2006) found a down-regulation of mRNA expression of apoA-I in 361 
salmon liver fed with 3-thia fatty acids, and Chen et al. (2009) obtained significant down-362 
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regulation at both protein and mRNA of apoA-I in an ayu, Plecoglossus altivelis, when 363 
transferred from freshwater to brackish water. To our knowledge, apoA-I has not been 364 
implicated with invermectin toxicity, but since the main role of apoA-I in liver is related to lipid 365 
transport and metabolism, a decrease in liver apoA-I could be important in the development 366 
of fatty livers in ivermectin treated fish at prolonged treatments or higher doses, as reported 367 
for many other compounds (xenobiotics) like hydrazine (KlenØ et al., 2004). It is known that 368 
hydrazine is a compound that causes a marked rise in the level of hepatic triglycerides 369 
(steatosis) in vivo. It has been pointed out that fatty livers of animals treated with hydrazine 370 
may be the result of decreased transport of lipids from the liver as apolipoproteins, due to low 371 
protein synthesis (Waterfield et al., 1997). In fact, KlenØ et al. (2004) found a down 372 
regulation in liver apolipoprotein A-IV (apo A-IV) in hydrazine treated rats, suggesting that the 373 
observed reduction of liver apo A-IV might be relevant to the development of fatty livers in 374 
rats after hydrazine treatment. 375 
 Beta globin (recommended name: haemoglobin subunit beta) is involved in oxygen 376 
transport and also possesses scavenging properties with free radicals and reactive oxygen 377 
and nitrogen species. It is believed that some of these reactions may be related to the 378 
defence of organisms against oxidative stress (Herold and Fago, 2005). In vivo, hepatic beta 379 
globin has been found over expressed in juveniles of the Senegalese sole, Solea 380 
senegalensis affected by gas bubble disease, and it was related to oxidative damage (Salas-381 
Leiton et al., 2009). We have found a reduction in the expression of beta globin at protein 382 
level but not at mRNA level after ivermectin treatment. Our findings may suggest that to a 383 
certain extent, ivermectin treatment could have affected the protection of the liver from 384 
oxidative stress, as described by Olsvik et al.  (2008) in Atlantic salmon treated with 385 
emamectin benzoate. These authors have also reported that a standard seven-day treatment 386 
has little effect on the transcription of genes in liver, although, this compound seems to 387 
produce a temporary oxidative stress response that affects protein stability and folding, 388 
followed by a secondary inflammatory response. 389 
  The ATP synthase subunit beta (spot 3913) identified by Mascot search in protein 390 
databases (SwissProt/Uniprot, NCBI) in the present study has been described in a bamboo 391 
palm, Chamaedorea seifrizzi as reference organism (see Table 1). However, a new search 392 
using BLASTP algorithm (protein-protein BLAST) revealed a sequence producing significant 393 
alignments of this protein with the annotation BAE45286.1 in GenBank, corresponding to an 394 
ATP synthase beta subunit described in rainbow trout, Oncorhynchus mykiss. The 395 
expression level of ATP synthase subunit beta was down regulated after ivermectin 396 
treatment. This protein is found mostly at the inner side of the mitochondrial membrane, but it 397 
has also been located at the cell surface (Martinez et al., 2003; Bae et al., 2004; Kim et al., 398 
2004). ATP synthase subunit beta is involved in ATP synthesis from ADP and phosphate in 399 
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the presence of a proton gradient across the membrane. Additionally, this protein is known to 400 
work as an apoA-I receptor in the plasma membrane to uptake high-density lipoprotein (HDL) 401 
into hepatocytes (Martinez el al., 2003). Previous studies have reported changes in the 402 
expression of ATP synthase subunit beta in relation to various toxicants (Chandra et al., 403 
2005; Kim et al., 2008; Qui et al., 2008). The decrease in the level of ATP synthase subunit 404 
beta protein found may reflect an effect of the mitochondrial respiration and thus an 405 
expression of alteration in the cellular energy metabolism as described by Chandra et al. 406 
(2005). These authors found a reduction in ATP synthase subunit beta in mouse 407 
macrophage cells treated with anthrax lethal toxin, suggesting that this toxin alters the 408 
mitochondrial respiration and acts as an uncoupler of oxidative phosphorylation, in 409 
consequence targeting cellular energy metabolism and eventually leading to cell death. Also, 410 
it is possible that the decrease in liver ATP synthase subunit beta may be directly involved in 411 
oxidative stress responses of liver to ivermectin treatment, since this protein is considered a 412 
part of the oxidative stress responses (Ding and Ong, 2003; Malécot et al., 2009). Besides, 413 
the decrease in ATP synthase subunit beta could be the cause of the reduced levels of 414 
apoA-I found, and both proteins may be related with a transient oxidative stress response   of 415 
liver to ivermectin treatment.  416 
In conclusion, this study has shown that a habitual ten-day ivermectin treatment at 417 
the recommended dose of 0.2 mg kg-1 fish induces some effects on the liver proteome of 418 
gilthead sea bream. The change in protein expression of a set of 36 proteins was able to 419 
separate medicated and control groups of fish, and may be considered as PES for 420 
hepatotoxicity of invermectin in this species. Hepatic proteins identified are involved in lipid 421 
metabolism (apoA-I), oxidative stress responses and energy generation (beta-globin, ATP 422 
synthase subunit beta). The down regulation of the identified proteins suggested that 423 
ivermectin might induce a reduced capacity to protect liver from oxidative damage.  Overall, 424 
the PES obtained and the proteins identified suggest a potential hepatotoxicity of ivermectin, 425 
at molecular level, after a standard treatment.  The proteomic approach used in this study 426 
was found to be a very sensitive tool to pinpoint unapparent subtle effects of xenobiotics at a 427 
molecular level. These effects may be possibly regarded as transient as described for other 428 
avermectins (Olsvik et al., 2008). Further studies are however necessary to confirm this fact. 429 
 430 
 431 
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Figure legends 569 
Fig. 1. Representative 2D-DIGE gel of soluble liver proteins extracted from gilthead sea 570 
bream (S. aurata).  3-10NL pH range were used for IEF. Protein spots differential expressed 571 
and identified are numbered as in table 2. In green dow-regulated spots and in red up-572 
regulated spots. 573 
 574 
Fig. 2. Multivariate analyses of liver proteomic data. (A) Principal Component Analysis (PCA) 575 
and hierarchical cluster analyses (B) of the proteins differentially expressed. PCA and the 576 
dendrogram after hierarchical analyses show a good separation of the spots maps 577 
corresponding to the different experimental groups (control in blue vs treated in red).  578 
 579 
Fig. 3. Relative liver gene expression of beta-globin and apoA-I in control and ivermectin 580 
treated fish. Values are means  sd (n = 4-6). Statistical differences were checked by t-test 581 
with a p-value of 0.05. 582 
 583 
Fig. 4. Histological sections of gilthead sea bream (S. aurata) from the liver of (A) control and 584 
(B) ivermectin treated fish.  585 
 586 
 587 
 588 
 589 
 590 
 591 
 592 
 593 
 594 
 595 
 596 
 597 
 598 
 599 
 600 
Table 1. Forward and reverse primers used in the real-time quantitative PCR assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
Gene Accession 
number 
 Primer sequence Position 
     
Apolipoprotein 
A-1 
AF013120 
F GAA TAC AAG GAG CAG ATG AAG CAG ATG 664-690 
R TGG TGA CGG AGG CAG CGA TG 808-789 
     
ß-globin AJ277207 
F TCA ATA TGG TCC AGT GGT CAG ATG C 58-82 
R AGC CTG AGA AGT GTC TTT GAG TCC 198-175 
     
α-tubulin AY326430 
F GAC ATC ACC AAT GCC TGC TTC 514-534 
R GTG GCG ATG GCG GAG TTC 647-630 
     
     
Table 1
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 Table 2 – Protein identities differentially expressed in the gilthead seabream (Sparus aurata) liver after treatment with 0.2 mg Kg-1 ivermectin 
for 10 days. p-value represents the significance level of t-test performed by the image analysis software DeCyder of up or down regulated 
spots. 
 
 
 
Spot 
nº 
 
Protein name 
 
Theo. MW/pI 
  
2D-DIGE 
 
Protein identification 
 
Function 
 
Reference 
organism 
Accession 
no.  
         PMF (MALDI TOFTOF) LC MS/MS     
    
        p-
value 
Av. Ratio  Score# matched %seq MSMS Score# Nº     
(fold 
induction) 
peptides cov peptides peptides   
  
3736 Beta-globin  16340/9,07  
gi|736322 
(P56251) 
0,0074 -1,65 193  6 48 4     Oxygen 
transport 
Sparus aurata 
3776 (hemoglogin 
subunit beta) 
0,0133 -2,1 245  7 60 3 
 
 
3784  0,0011 -2,4 183 8 69 3     
3838  0,0090 -1,84 266  8 61 3     
3841  0,0021 -1,94 172 9 85 2     
3993 Apolipoprotein 
A-1  
29615/5,21 gi|2511712 0,0183 -1,8 95 13 72 2     Cholesterol  Sparus aurata 
3992 29615/5,04  0,0011 -1,41 131 9 49 1 metabolism  
                    
3074 unnamed 
protein 
product 
 27847/5,41 gi|47211357 0,0020 -1,51      51 1 unknown Tetradon 
nigroviridis 
3760 unnamed 
protein 
product 
 85031/9,32 gi|47228876 0,0035 -1,45      47 1 unknown Tetradon 
nigroviridis 
3913 ATP synthase 
subunit beta                      
53795/5,22 gi|34582342 
(Q9MU80.1) 
0,0007 -1,53 66 11 38 1  
  
ATP 
synthesis 
Chamaedorea 
seifrizii  
           
  
 
 
Accession nº: NCB nº (SWISS PROT nº) 
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